Table 2. Influence of miR-346 expression and clinical characteristics on overall survival in NSCLC patients.
| Factors | Subset | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|---|
| HR (95%CI) | P-value | HR (95%CI) | P-value | ||
| Age(years) | >60/≤60 | 2.18 (1.09-2.24) | 0.013 | 1.09 (0.45-0.84) | 0.796 |
| Sex | Male/Female | 0.94 (0.55-1.70) | 0.805 | ||
| Differentiation | Poor /Well, moderate | 1.26 (0.75-1.66) | 0.678 | ||
| Tumor size | >3cm/≤3cm | 1.78 (0.95-2.48) | 0.093 | ||
| Smoking | Yes/No | 1.60 (0.66-2.33) | 0.417 | ||
| Lymph node metastasis | Positive/ Negative | 2.31 (1.02-3.06) | 0.008 | 2.87 (1.34-5.08) | 0.001 |
| TMN stage | (II/III/IV)/I | 2.27 (1.23-3.59) | 0.003 | 2.52 (1.14-3.62) | 0.002 |
| miR-346 | High/Low | 6.88 (3.12-8.53) | <0.001 | 7.645 (3.88-14.30) | <0.001 |
| Histological tumor type | Squamous cell carcinoma/Adenocarcinoma | 1.88 (0.86-2.63) | 0.717 | ||
HR, hazard ratio; CI, confidence interval.